Effect of Natural HIV-1 Envelope V1-V2 Sequence Diversity on the Binding of V3-Specific and Non-V3-Specific Antibodies
- 1 October 1997
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 16 (2) , 69-73
- https://doi.org/10.1097/00042560-199710010-00001
Abstract
In past years, much attention has been paid to the HIV-1 envelope (env) protein variable region 3 (V3), termed the principal neutralizing determinant. HIV-1 vaccines were often designed to target V3, and vaccine efficacy was often measured with V3-based assays. Thus, some disappointment resulted when volunteers in first clinical vaccine trials generated V3-specific antibodies that could not protect against V3-similar viruses. We describe an analysis of V1 and V2 sequence effects on antibody binding to V3 and non-V3 determinants. This study involved the preparation of seven full-length (gp160), chimeric env proteins in a vaccinia virus (VV) expression system. Chimeric proteins displayed different V1-V2 sequences but were otherwise identical. A panel of 12 monoclonal antibodies was then tested for binding activities toward the seven chimeras. Results showed that V1-V2 sequences affected antibody binding to env, both in V3 and non-V3 positions. These data demonstrate the enormous complexity of HIV-1 env protein conformation and antigenic determinants. Respect for the complexity of antibody-antigen interactions encourages the design of sophisticated immunoglobulin and protein cocktails for use in HIV-1 therapies and vaccines, respectively.Keywords
This publication has 30 references indexed in Scilit:
- Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor bindingJournal of Virology, 1995
- Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal AntibodyScience, 1994
- HIV Type 1 Envelope Sequence Diversity in Inner City CommunityAIDS Research and Human Retroviruses, 1994
- Epitope Mapping and Topology of Baculovirus-Expressed HIV-1 gp160 Determined with a Panel of Murine Monoclonal AntibodiesAIDS Research and Human Retroviruses, 1994
- Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibodyJournal of Virology, 1993
- Broadly Neutralizing Monoclonal Antibodies to the V3 Region of HIV-1 Can Be Elicited by Peptide ImmunizationVirology, 1993
- Prevention of HIV Infection by Passive Immunization with HIV ImmunoglobulinAIDS Research and Human Retroviruses, 1991
- Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Proceedings of the National Academy of Sciences, 1989
- Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV.Proceedings of the National Academy of Sciences, 1988
- Complete nucleotide sequence of the AIDS virus, HTLV-IIINature, 1985